Innohep

Tinzaparin Sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a subcutaneous injection for anticoagulant use. It helps prevent and treat thrombotic conditions such as deep vein thrombosis and pulmonary embolism in at‑risk patients.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat venous thromboembolism.

- Prevention of deep vein thrombosis: reduces clot formation in patients undergoing surgery or prolonged immobilisation. - Treatment of deep vein thrombosis: facilitates clot resolution and prevents extension of existing thrombi. - Prevention of pulmonary embolism: lowers the incidence of embolic events in high‑risk individuals.

Common Side Effects: - Injection site erythema or pain: mild local irritation at the subcutaneous site. - Bruising or haematoma: small bleeding under the skin around the injection. - Mild gastrointestinal upset: occasional nausea or dyspepsia.

Serious or Rare Side Effects: - Major bleeding: potentially life‑threatening haemorrhage in any organ. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet drop with paradoxical clot risk. - Spinal or epidural haematoma: rare but severe bleeding in neuraxial spaces. - Severe allergic reaction: anaphylaxis or urticaria. - Elevated liver enzymes: transient hepatic enzyme rise.

Innohep requires careful clinical assessment before use. - Renal impairment: adjust dose and monitor anti‑Xa activity. - History of HIT: avoid use due to cross‑reactivity. - Concurrent anticoagulants: increased bleeding risk; evaluate necessity. - Upcoming surgery or invasive procedures: discontinue according to protocol. - Pregnancy: use only if potential benefit outweighs risk. - Store below 25°C: keep in original container, protect from moisture and light.

Tinzaparin sodium may interact with several agents that affect haemostasis.

Major Interactions (Avoid): - Concomitant warfarin: synergistic anticoagulation leading to severe bleeding. - Use with other heparins (LMWH or unfractionated): additive anticoagulant effect. - Combination with high‑dose antiplatelet agents (e.g., clopidogrel, aspirin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs (ibuprofen, naproxen): may increase minor bleeding tendencies. - SSRIs or SNRIs (e.g., sertraline, venlafaxine): potential for enhanced mucosal bleeding.